In the last three months, 8 analysts have published ratings on United Therapeutics UTHR, offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 1 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 1 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $356.38, a high estimate of $400.00, and a low estimate of $280.00. Observing a 11.46% increase, the current average has risen from the previous average price target of $319.75.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive United Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tiago Fauth | Wells Fargo | Raises | Overweight | $380.00 | $350.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $400.00 | $400.00 |
| Greg Harrison | B of A Securities | Lowers | Underperform | $280.00 | $303.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $400.00 | $300.00 |
| Joseph Thome | TD Cowen | Raises | Buy | $350.00 | $270.00 |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $321.00 | $310.00 |
| Ashwani Verma | UBS | Raises | Buy | $370.00 | $300.00 |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $350.00 | $325.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on United Therapeutics analyst ratings.
Delving into United Therapeutics's Background
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Unraveling the Financial Story of United Therapeutics
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.85%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.9%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA excels beyond industry benchmarks, reaching 4.21%. This signifies efficient management of assets and strong financial health.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
